Metformin is an effective, cheap, and safe drug used as the first-line agent for treating type 2 diabetes (T2D) ([@B1]--[@B3]). Nevertheless, hyperglycemia eventually progresses in many patients, causing escalation of therapy ([@B4]). The reasons for such failure, which takes some time to become apparent, are unknown. Genetic factors may contribute to this process.

Recently, a genome-wide association study (GWAS) for metformin response has been published ([@B5]). The Genetics of Diabetes Audit and Research Tayside (GoDARTS) investigators analyzed 705,125 single nucleotide polymorphisms (SNPs) in 1,024 individuals who had a definable metformin response in a retrospective clinical database. Treatment success (analyzed as a categorical trait) was declared if glycated hemoglobin (A1C) became ≤7% within 18 months of starting therapy; change in A1C was also analyzed as a quantitative trait. Fourteen SNPs, concentrated around the ataxia-telangiectasia--mutated (*ATM*) gene, were associated with categorical metformin response at a suggestive level of *P* \< 10^−6^. Consistent results were obtained for metformin response as a quantitative trait. The top SNP (rs11212617) was genotyped in 1,783 additional GoDARTS participants and 1,113 participants in the UK Prospective Diabetes Study (UKPDS) clinical trial ([@B6]). Again, in both cohorts, its minor C allele (frequency 44%) was nominally associated with greater metformin response, either as a categorical or quantitative trait. Joint analysis exceeded conventional genome-wide statistical significance (*P* = 2.9 × 10^−9^), i.e., this *P* value withstands correction for multiple comparisons. We therefore tested this SNP for metformin response in the Diabetes Prevention Program (DPP), a clinical trial with participants from five U.S. ethnic groups who were at high risk of T2D and were treated with an intensive lifestyle intervention or metformin for diabetes prevention.

RESEARCH DESIGN AND METHODS {#s1}
===========================

Participants {#s2}
------------

The DPP enrolled 3,234 overweight or obese, nondiabetic people with impaired glucose tolerance. They were randomized to placebo, metformin (850 mg twice daily), or a lifestyle intervention. The participants' mean age was 51 years and mean BMI was 34.0 kg/m^2^, 68% were women, and 45% belonged to U.S. ethnic minority groups; their demographic characteristics are shown in [Table 1](#T1){ref-type="table"}. The lifestyle and metformin interventions reduced the incidence of diabetes by 58 and 31%, respectively, versus placebo ([@B7]). In total, 2,994 participants (988 on metformin) consented to genetic investigation. All procedures were approved by institutional review boards at the 27 study sites.
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Demographic characteristics of the DPP cohort by treatment arm and genotype at rs11212617
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Genotyping {#s3}
----------

We genotyped rs11212617 on a Sequenom iPLEX platform as previously described ([@B8],[@B9]). Genotyping success was 99.9%.

Measurements {#s4}
------------

Diabetes incidence was determined by semiannual measurements of fasting glucose and an annual oral glucose tolerance test. The principal study outcome was the development of diabetes by American Diabetes Association criteria, including confirmation. Besides diabetes incidence as a categorical outcome, we selected the insulin sensitivity index (ISI), fasting glucose, A1C, weight, and oral disposition index (DIo) as indices of metformin response. We calculated the ISI as 22.5/(\[fasting insulin × fasting glucose\]/18.01) (or 1/homeostasis model assessment of insulin resistance) ([@B10]), and the DIo as 1/fasting insulin × insulinogenic index (Δinsulin/Δglucose over the first 30 min of the oral glucose tolerance test) ([@B11]). Quantitative traits were natural log--transformed.

Statistical analysis {#s5}
--------------------

We tested the additive effect of genotype at rs11212617 on diabetes incidence by Cox proportional hazards regression models with genotype and intervention and their interactions as the independent variables predicting time to diabetes over mean 3.2 years follow-up, adjusted for sex, ethnicity, treatment arm, baseline age, and waist circumference. We included all three treatment arms and an interaction test to simultaneously rule out a main effect of this variant on diabetes incidence independent of metformin, or under the action of a lifestyle intervention. We used generalized mixed models to test additive effect of genotype on baseline log-transformed traits and, to model change under metformin action, on the same traits after 1 year of intervention adjusted for the baseline value of the respective trait, age, sex, ethnicity, treatment arm, and waist circumference. Post hoc power calculations (which should be interpreted with caution) show that the sample size in the DPP metformin arm has \>99% power to detect the change in A1C of 0.61% that was reported in the UKPDS ([@B5]). To control for the potential effect of ethnicity, we performed sensitivity analyses in the largest race/ethnic group (white participants), which is most closely related to the populations examined in the original report and whom we have previously shown to be essentially free of non-European admixture ([@B12]).

RESULTS {#s6}
=======

The frequency of the C (metformin-responsive) allele was 42.4, 72.4, 40.1, 51.6, and 41.5% in 1,669 white, 609 African American, 497 Hispanic, 127 Asian/Pacific Islander, and 82 American Indian participants, respectively ([Table 1](#T1){ref-type="table"}). We found no association of genotype with diabetes incidence in all arms combined, either in unadjusted analyses (hazard ratio \[HR\] per copy of the C allele 0.98 \[95% CI 0.88--1.10\], *P* = 0.76) or after adjusting for age, sex, ethnicity, and treatment arm (HR per copy of the C allele 0.95 \[0.85--1.07\], *P* = 0.42); further adjustment for waist circumference produced indistinguishable results ([Table 2](#T2){ref-type="table"}). There was no significant genotype × metformin interaction in the unadjusted model. Though there was a nominal SNP × metformin interaction in the fully adjusted model (*P* = 0.04), the observed trend was in the opposite direction from the expected prevention effect; the C allele conferred no detectable advantage on metformin recipients in diabetes prevention but was associated with a nonsignificant trend toward increased risk of diabetes (HR per copy of the C allele 1.17 \[0.96--1.42\], *P* = 0.13). We found no significant associations of genotype with relevant quantitative glycemic traits at baseline; similarly, there were no significant differences across genotype groups in change in ISI, fasting glucose, A1C, or DIo after 1 year of metformin ([Table 3](#T3){ref-type="table"}). The C allele was associated with greater weight gain in the metformin arm. In this arm, there were no statistically significant interactions between the C allele and BMI or waist circumference on diabetes incidence. Analyses stratified by ethnic group failed to show any ethnic-specific beneficial effects of the C allele with regard to diabetes incidence on metformin-treated participants ([Table 4](#T4){ref-type="table"}).
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Diabetes incidence in the DPP by genotype at rs11212617, treatment arm, and self-reported ethnicity
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###### 

Association of rs11212617 with quantitative glycemic traits at 1 year
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###### 

Ethnic-specific effects of rs11212617 on diabetes incidence in the DPP
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CONCLUSIONS {#s7}
===========

In the DPP, the effect of metformin to prevent diabetes or improve relevant glycemic traits was not magnified among carriers of the C allele at rs11212617 in the *ATM* gene. Our findings do not support the previously reported association of this allele with improved metformin action on glycemic control. The original association was consistent in three different datasets (the discovery sample and two follow-up cohorts) and has been reported recently in other clinical cohorts similarly ascertained ([@B13]). Inconsistent results in the DPP could be due to multiple reasons. First, metformin response is defined differently in a prediabetic cohort (impact on diabetes incidence or quantitative glycemic traits) than it is in a disease cohort (ability to reach A1C ≤7% under treatment). Second, metformin may be more effective in individuals with a higher A1C at baseline, and thereby the effects of genotype on response might be easier to detect in the disease setting. Third, the reported effect might be confined to populations of European descent, e.g., if rs11212617 tags a low-frequency variant unique to white populations, further diminishing statistical power in the DPP multiethnic cohort. And fourth, the previously reported GWAS was based on a retrospective evaluation of clinical records, where potential confounders (e.g., if genotype were to influence comorbidities that affect patient adherence, continuity of care, or frequency of A1C measurements) are harder to control than in a clinical trial.

To address potential ethnic differences in the genomic architecture of this region that might explain our negative results, we examined the haplotype structure around this locus in the HapMap European (CEU) and West African (YRI) datasets. The full *ATM* gene and the rs11212617 variant share a segment of tight linkage disequilibrium in both the CEU and YRI populations; there is a recombination hot spot downstream from rs11212617, beyond which SNPs display equally low correlations with rs11212617 in CEU and YRI, indicating that major differences in linkage disequilibrium patterns would be unlikely to account for potentially discrepant findings in Europeans and Africans. Furthermore, the region distal to this hot spot was well captured by the original GWAS array, suggesting that a true signal emerging from this region (and which might have explained a stronger association in Europeans than in Africans) would have also been detected by the original GWAS.

Nevertheless, this previously reported association merits additional follow-up in independent cohorts. More generally, a better-powered genome-wide assessment of pharmacogenetic responses in T2D is needed; whether genetic information will prove useful in diabetes prevention or therapeutics must be tested in prospective clinical trials.

Clinical trial reg. no. NCT00004992, [clinicaltrials.gov](clinicaltrials.gov).

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-2301/-/DC1>.
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